

34. Public Health England (PHE). *SARS-CoV-2 Variants of Concern and Variants under Investigation..Technical Briefing 18.*; 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1001358/Variants_of_Concern_VOC_Technical_Briefing_18.pdf
35. Altarawneh H, Chemaitelly H, Tang P, et al. *Protection Afforded by Prior Infection against SARS-CoV-2 Reinfection with the Omicron Variant.* *Epidemiology*; 2022. doi:10.1101/2022.01.05.22268782
36. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. Accessed November 30, 2021. [https://www.who.int/news/item/26-11-2021-classification-of-omicron-\(b.1.1.529\)-sars-cov-2-variant-of-concern](https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern)
37. Public Health England. SARS-CoV-2 lateral flow antigen tests: evaluation of VOC1 (Kent, UK) and VOC2 (South Africa). GOV.UK. Accessed June 21, 2021. <https://www.gov.uk/government/publications/sars-cov-2-lateral-flow-antigen-tests-evaluation-of-voc1-and-voc2/sars-cov-2-lateral-flow-antigen-tests-evaluation-of-voc1-kent-uk-and-voc2-south-africa>
38. Bekliz M, Adea K, Essaidi-Laziosi M, et al. *Analytical Performance of Eleven SARS-CoV-2 Antigen-Detecting Rapid Tests for Delta Variant.* *Infectious Diseases (except HIV/AIDS)*; 2021. doi:10.1101/2021.10.06.21264535
39. Molenkamp R, Igloi Z. Evaluation of Antigen rapid test and PCR test to Omicron variant. file:///C:/Users/bookelh/Downloads/2021-Evaluation-Omicron-in-PCR-and-Ag-assays%20(1).pdf
40. Goderski G HW, Stanoeva K MA. Technical evaluation of SARS-CoV-2 antigen self-tests with Omicron variant , Final Evaluation report.
41. Adamson B, Sikka R, Wyllie AL, Premsrirut P. *Discordant SARS-CoV-2 PCR and Rapid Antigen Test Results When Infectious: A December 2021 Occupational Case Series.* *Infectious Diseases (except HIV/AIDS)*; 2022. doi:10.1101/2022.01.04.22268770
42. Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. *JAMA*. Published online January 21, 2022. doi:10.1001/jama.2022.0470
43. Tartof SY, Slezak JM, Puzniak L, et al. *BNT162b2 (Pfizer–Biontech) MRNA COVID-19 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a Large US Health System: A Test-Negative Design.* *Social Science Research Network*; 2022. doi:10.2139/ssrn.4011905
44. Young-Xu Y. Effectiveness of mRNA COVID-19 Vaccines against Omicron among Veterans. Published online January 18, 2022:2022.01.15.22269360. doi:10.1101/2022.01.15.22269360
45. Suaah JL, Husin M, Tok PSK, et al. Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study. Published online January 16, 2022:2022.01.15.22269326. doi:10.1101/2022.01.15.22269326
46. Olson SM, Newhams MM, Halasa NB, et al. Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents. *N Engl J Med*. Published online January 12, 2022:NEJMoa2117995. doi:10.1056/NEJMoa2117995
47. Chiew CJ, M P, Wei WE, et al. *Vaccine Effectiveness Against COVID-19 Infection Among 12 to 18 Year Olds in Singapore.* *Social Science Research Network*; 2021. doi:10.2139/ssrn.3996796
48. Waxman J, Makov-Assif M, Reis B, et al. Comparison of Natural and BNT162b2 Vaccine-induced Immunity, with and without an Enhancer or Booster Dose, on the Risk of COVID-19-Related Hospitalization in Israel. Published online January 23, 2022. doi:10.21203/rs.3.rs-1177969/v1
49. Spitzer A, Angel Y, Marudi O, et al. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel. *JAMA*. Published online January 10, 2022. doi:10.1001/jama.2021.23641